YiChang SanXia Pharmaceutical Co., Ltd.
-
Founded in:
1999-07-20 -
Country:
China -
Address:
No. 8 Ziyang Road, Dianjun District, Yichang City -
Tax NO.:
91420500753443535T -
Registered Funds:
390 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Lincomycin hydrochloride |
It has high antibacterial activity against common aerobic Gram-positive bacteria, such as Staphylococcus aureus (including those resistant to penicillin G), Staphylococcus epidermidis, beta-hemolytic Streptococcus, viridans Streptococcus and Streptococcus pneumoniae. It has good antibacterial effect on anaerobic bacteria, including Clostridium diphtheriae, and Clostridium perfringens. It has no activity against Gram-negative bacteria such as Enterococcus, meningococci, Neisseria gonorrhoeae, and Haemophilus influenzae, as well as fungi. There is no cross-resistance with penicillin, chloramphenicol, cephalosporins and tetracyclines, and there is partial cross-resistance with macrolides. It acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.
More
It has high antibacterial activity against common aerobic Gram-positive bacteria, such as Staphylococcus aureus (including those resistant to penicillin G), Staphylococcus epidermidis, beta-hemolytic Streptococcus, viridans Streptococcus and Streptococcus pneumoniae. It has good antibacterial effect on anaerobic bacteria, including Clostridium diphtheriae, and Clostridium perfringens. It has no activity against Gram-negative bacteria such as Enterococcus, meningococci, Neisseria gonorrhoeae, and Haemophilus influenzae, as well as fungi. There is no cross-resistance with penicillin, chloramphenicol, cephalosporins and tetracyclines, and there is partial cross-resistance with macrolides. It acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria. |
859-18-7 | 30 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| ATP disodium salt |
This product is a coenzyme that improves the body's metabolism and participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotides in the body. It is also the main source of energy in the body. When energy is needed for absorption, secretion, muscle contraction and biochemical synthesis reactions in the body, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time. Animal experiments have shown that this product can inhibit the slow calcium ion influx of slow-reacting fibers, block or delay the forward conduction in the atrioventricular node reentry pathway, and a large dose may also block or delay the forward and reverse conduction of the bypass; in addition, it also has a short-term and strong effect of enhancing the vagus nerve, thereby terminating arrhythmias caused by atrioventricular node reentry and bypass reentry mechanisms.
More
This product is a coenzyme that improves the body's metabolism and participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotides in the body. It is also the main source of energy in the body. When energy is needed for absorption, secretion, muscle contraction and biochemical synthesis reactions in the body, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time. Animal experiments have shown that this product can inhibit the slow calcium ion influx of slow-reacting fibers, block or delay the forward conduction in the atrioventricular node reentry pathway, and a large dose may also block or delay the forward and reverse conduction of the bypass; in addition, it also has a short-term and strong effect of enhancing the vagus nerve, thereby terminating arrhythmias caused by atrioventricular node reentry and bypass reentry mechanisms. |
987-65-5 | 8 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium chloride |
Maintain normal blood and extracellular fluid volume and osmotic pressure
More
Maintain normal blood and extracellular fluid volume and osmotic pressure |
0.85% | 7647-14-5 | 43 |
| Potassium chloride |
Supplement potassium ions and participate in maintaining body fluid volume and electrolyte balance
More
Supplement potassium ions and participate in maintaining body fluid volume and electrolyte balance |
0.03% | 7447-40-7 | 39 |
| Calcium chloride |
Supplement calcium ions and regulate water and electrolyte balance
More
Supplement calcium ions and regulate water and electrolyte balance |
0.033% | 10043-52-4 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Pefloxacin mesylate |
Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.
More
Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci. |
70458-95-6 | 4 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium lactate |
The final metabolite is sodium bicarbonate, which can correct metabolic acidosis; when hyperkalemia is accompanied by acidosis, it can correct acidosis and allow potassium ions to enter cells from the blood and extracellular fluid.
More
The final metabolite is sodium bicarbonate, which can correct metabolic acidosis; when hyperkalemia is accompanied by acidosis, it can correct acidosis and allow potassium ions to enter cells from the blood and extracellular fluid. |
3.10g | 312-85-6 | 0 |
| Sodium chloride |
Under normal circumstances, human blood also contains a small amount of lactic acid, which is mainly produced by glucose or glycogenolysis, and comes from muscles, skin, brain and cells. After lactic acid is produced, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor.
More
Under normal circumstances, human blood also contains a small amount of lactic acid, which is mainly produced by glucose or glycogenolysis, and comes from muscles, skin, brain and cells. After lactic acid is produced, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor. |
6.00g | 7647-14-5 | 43 |
| Potassium chloride |
When hyperkalemia is accompanied by acidosis, potassium ions can enter cells from the blood and extracellular fluid.
More
When hyperkalemia is accompanied by acidosis, potassium ions can enter cells from the blood and extracellular fluid. |
0.30g | 7447-40-7 | 39 |
| Calcium chloride |
Under normal circumstances, human blood also contains a small amount of lactic acid, which is mainly produced by glucose or glycogenolysis, and comes from muscles, skin, brain and cells. After lactic acid is produced, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor.
More
Under normal circumstances, human blood also contains a small amount of lactic acid, which is mainly produced by glucose or glycogenolysis, and comes from muscles, skin, brain and cells. After lactic acid is produced, it may be converted into glycogen or acetic acid, or enter the tricarboxylic acid cycle and be decomposed into water and carbon dioxide. Therefore, the final metabolite of sodium lactate is sodium bicarbonate, which can correct metabolic acidosis. When hyperkalemia is accompanied by acidosis, sodium lactate can correct acidosis and allow potassium ions to enter cells from blood and extracellular fluid. The main organs that degrade lactic acid are liver and kidney. When lactic acid metabolism in the body is abnormal or impaired, the therapeutic effect is poor. |
0.2g | 10043-52-4 | 29 |